Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
|
|
9.
|
|
|
10.
|
|
|
11.
|
|
|
12.
|
|
|
13.
|
|
|
14.
|
|
|
15.
|
|
|
16.
|
|
|
17.
|
|
|
18.
|
Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. [electronic resource] by
- Tedesco, K L
- Thor, A D
- Johnson, D H
- Shyr, Y
- Blum, K A
- Goldstein, L J
- Gradishar, W J
- Nicholson, B P
- Merkel, D E
- Murrey, D
- Edgerton, S
- Sledge, G W
Producer: 20040408
In:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology vol. 22
Availability: No items available.
|